IQV trades 8.1% above Wall Street's consensus target of $246.13.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IQV achieves its forward estimates and maintains a stable P/E multiple of 20.7x. This scenario reflects the blended consensus of 45 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, IQVIA Holdings Inc. (IQV) has a Wall Street consensus price target of $246.13, based on estimates from 45 covering analysts. With the stock currently trading at $267.86, this represents a potential downside of -8.1%. The company has a market capitalization of $44.09B.
Analyst price targets range from a low of $185.00 to a high of $287.00, representing a 41% spread in expectations. The median target of $243.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 37 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IQV trades at a trailing P/E of 34.2x and forward P/E of 20.7x. The forward PEG ratio of 0.51 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +59.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $273.40, with bear and bull scenarios of $172.24 and $360.23 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
 ICLRICON Public Limited Company | $12.5B | $163.90 | $170.64 | +4.1% | Buy | 15.5x | 30 |
 PRAProAssurance Corporation | $1.3B | $25.00 | $18.33 | -26.7% | Hold | 20.4x | 11 |
 MEDPMedpace Holdings, Inc. | $17.2B | $617.15 | $606.38 | -1.7% | Hold | 35.1x | 19 |
 VEEVVeeva Systems Inc. | $44.0B | $270.75 | $290.50 | +7.3% | Buy | 29.3x | 43 |
 INCYIncyte Corporation | $25.3B | $124.64 | $130.07 | +4.4% | Buy | 33.1x | 44 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 HCATHealth Catalyst, Inc. | $127M | $1.72 | $1.77 | +2.9% | Buy | — | 22 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
 CVSCVS Health Corp. | $109.6B | $85.86 | $111.20 | +29.5% | Buy | 10.7x | 41 |
Quick answers to the most common questions about buying IQV stock.
Wall Street's consensus price target for IQV is $246.13, -8.1% from its current price of $267.86. The below-market target from 45 analysts suggests limited near-term appreciation.
IQV has a consensus rating of "Buy" based on 45 Wall Street analysts. The rating breakdown is predominantly bullish, with 37 Buy/Strong Buy ratings. The consensus 12-month price target of $246.13 implies -8.1% downside from current levels.
IQV trades at a forward P/E of 20.6553x, representing a moderate valuation. With analysts targeting $246.13 (-8.1% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $287 for IQV, while the most conservative target is $185. The consensus of $246.13 represents the median expectation. Our quantitative valuation model projects a bull case target of $360 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IQV is heavily covered by Wall Street, with 45 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 36 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IQV stock forecast based on 45 Wall Street analysts shows a consensus price target of $246.13, with estimates ranging from $185 (bear case) to $287 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $273, with bear/bull scenarios of $172/$360.
Our quantitative valuation model calculates IQV's fair value at $273 (base case), with a bear case of $172 and bull case of $360. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
IQV trades at a forward P/E ratio of 20.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on IQV, with 1 Sell ratings and a price target of $246.13 (-8.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IQV analyst price targets range from $185 to $287, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $246.13 consensus represents the middle ground. Our model's $172-$360 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.